Solutions
Advisory Services
Clinical Development
- Generics Development
- Clinical Operations
- Clinical Data Sciences
- Medical and Safety Services
- RWD & RWE Services
Post Marketing
- Safety Services
- Post marketing Studies
- Regulatory Affairs
Boutique by Design. Outcome-focused by Model. As clinical trials become increasingly complex, sponsors need more than functional support, they need expert clinical data science expertise that transforms data into confident decisions. The clinical research industry is entering a new phase of complexity. Global clinical trials are becoming larger, mo...
How biotech companies can identify the right CRO partner to accelerate patient recruitment, improve trial quality, reduce operational burden and deliver regulatory-ready data. The way clinical trials are conducted has changed dramatically over the last five years. What began as a necessity during the COVID-19 pandemic has evolved into a strategic a...
Pharmaceutical organizations are facing a new challenge that goes beyond clinical development, pharmacovigilance and regulatory submissions: controlling who can access sensitive data, where they can access it from and how every access decision is documented. Regulatory changes, strengthened national security requirements and increasingly complex cr...
Bringing a new therapy to market is one of the most significant milestones in a pharmaceutical or biotechnology company's journey. Yet, while organizations invest substantial resources in clinical development, regulatory submissions and commercialization planning, many underestimate the complexity of building a compliant and scalable pharmacovigila...
Biotech and pharma companies face increasing pressure to accelerate timelines, manage costs, cater to regulatory changes and maintain quality across global programs. As clinical trials become more complex, selecting the right outsourcing model has become a strategic decision rather than simply an operational one. Among the most widely adopted appro...
How integrated clinical, regulatory, pharmacovigilance and data science ecosystems are accelerating global development programs Insights ahead of the 2026 DIA China Annual Meeting Global drug development is becoming increasingly complex and sponsors need to manage changing regulatory requirements, decentralized trial models, increasing operational ...
Selecting the right clinical research organization (CRO) can determine the success or failure of a biotech company’s clinical program. With increasing complexity in clinical trials, regulatory demands and cost pressures, choosing the right CRO partner is more critical than ever. Yet many biotech companies continue to make avoidable mistakes ...
The conversation around R programming has fundamentally changed. What was once viewed as a niche statistical language, largely confined to academia, has steadily grown into a strategic capability for data-driven organizations, particularly in high-stakes, data-intensive industries such as clinical research, pharmaceuticals and biotech. Yet, despite...
SAHPRA Application ID Update 2025: Impact on eCTD Submission and eCTD Publishing The South African Health Products Regulatory Authority (SAHPRA) released an important communication (Issue No.: HPA16-2025/26) introducing a standardized Application ID system that directly impacts eCTD submission, dossier structuring, and eCTD publishing workflows. Th...
In 2001, a small group of life sciences leaders came together with a simple but unconventional idea, to create a space where industry peers could collaborate, benchmark and solve shared challenges. At the time, pharmacovigilance and regulatory environments were fragmented, largely manual and defined by siloed decision-making. Structured, peer-to-pe...